Sumitomo Chemical Company, Limited

Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo

Haruki Okamura

Tamaki Ishii

Shinichi Yachigo

Manji Sasaki

Masashi Kurimoto

Kakuji Torigoe

Keizo Kohno

Mutsuko Taniguchi

Tatsuo Kaneoya

Yukoh Takahashi

Tadao Tanimoto

Toshio Kunikata

Yuzo Maegawa

Chinehito Ebina

Eizo Okino

Masahisa Shionoya

Shimpei Ushio

Shigeharu Fukuda

Tetsuo Yamaguchi

Hiroki Yamamoto

Toshi Kunikata

Todao Tanimoto

Takeshi Takata

Takeo Fujii

Osamu Moriya

Shin-ichi Yachigo

Seiji Koono

Toshio Noguchi

Masahisa Shinoya

Akinori Okamoto

A protein which induces the IFN-&#x3b3; production by immunocompetent cells and has a molecular weight of 19,000&#xb1;5,000 daltons on SDS-PAGE or gel filtration method and a pI of 4.8&#xb1;1.0 on chromatofocusing. The protein is isolated from mouse liver and can be purified by a monoclonal antibody specific to it. The monoclonal antibody can be also used for assaying the protein.

IFN-&#x3b3; production inducing protein (IGIF, IL-18)

A human IFN-&#x3b3; inducing polypeptide and its nucleotide sequence was isolated, purified and characterized. Pharmaceutical compositions containing this novel INF-&#x3b3; inducing polypeptide or active fragments thereof are formulated and monoclonal antibodies are raised against this polypeptide or antigenic fragments thereof. The polypeptide can be used in a method for treating diseases susceptive to treatment with INF-&#x3b3;, and methods for enhancing the cytotoxicity of NK cells or for inducing the formation of LAK cells, such as to treat tumors and malignant pathologies.

Interferon-&#x3b3; inducing polypeptide, pharmaceutical composition thereof, monoclonal antibody thereto, and methods of use

A human IFN-&#x3b3; inducing polypeptide and its nucleotide sequence was isolated, purified and characterized. Pharmaceutical compositions containing this novel IFN-&#x3b3; inducing polypeptide or active fragments thereof are formulated and monoclonal antibodies are raised against this polypeptide or antigenic fragments thereof. The polypeptide can be used in a method for treating diseases susceptive to treatment with IFN-&#x3b3;, and methods for enhancing the cytotoxicity of NK cells or for inducing the formation of LAK cells, such as to treat tumors and malignant pathologies.

A protein which induces the IFN-&ggr; production by immunocompetent cells and has a molecular weight of 19,000&plusmn;5,000 daltons on SDS-PAGE or gel filtration method and a pI of 4.8&plusmn;1.0 on chromatofocusing. The protein is isolated from mouse liver and can be purified by a monoclonal antibody specific to it. The monoclonal antibody can be also used for assaying the protein. Fragments of the protein can be used for production of antibodies, and can be produced recombinantly using appropriate medric acids, host cells and vectors. Fragments of nuclear acids may also be used as probes.

DNA molecule encoding interferon-gamma (IFN-&lgr;) inducing factor (IGIF, IL-18) and DNA fragment thereof

A protein which induces the IFN-&ggr; production by immunocompetent cells and has a molecular weight of 19,000&plusmn;5,000 daltons on SDS-PAGE or gel filtration method and a pI of 4.8&plusmn;1.0 on chromatofocusing. The protein is isolated from mouse liver and can be purified by a monoclonal antibody specific to it. The monoclonal antibody can be also used for assaying the protein.

Interferon-gamma (IFN-&ggr;) inducing factor (IGIF, IL-18) and peptide fragment thereof

A polypeptide which has a molecular weight of 18,500&plusmn;3,000 daltons on SDS-PAGE and a pI of 4.9&plusmn;1.0 on chromatofocusing. The polypeptide strongly induces the IFN-&ggr; production by immunocompetent cells with only a small amount, and does not cause serious side effects even when administered to human in a relatively-high dose. It can be used to treat and/or prevent malignant tumors, viral diseases, bacterial infectious diseases, and immune diseases.

Human Interferon-&ggr;inducing factor

DNA encoding a murine protein capable of inducing the production of interferon-.gamma. by immunocompetent cells is described. The native protein from mouse liver has a molecular weight of 19.+-.5 kDa, a pI of 4.8.+-.1.0, and the amino acid sequence shown in SEQ ID NO: 2. Methods for producing the protein in recombinant expression systems including E. coli are provided.

Recombinant production of murine interferon--.gamma. (IFN-.gamma.)

A protein which induces IFN-.gamma. production by immunocompetent cells and has a molecular weight of 19,000.+-.5,000 daltons on SDS-PAGE or gel filtration and a pI of 4.8.+-.1.0 on chromatofocusing. The protein is isolated from mouse liver and can be purified by a monoclonal antibody specific to it. The monoclonal antibody can be also used for assaying the protein.

Interferon-gamma (IFN-.gamma.) inducing factor (IGIF, IL-18) purified

A process for producing a carboxylic acid ester which comprises reacting a carboxylic acid with an alcohol in the presence of an acid catalyst to produce a reaction solution and neutralizing the reaction solution, characterized by using a countercurrently contacting column for neutralization, into which the esterified reaction solution is introduced at the lower portion of the column, an aqueous strong alkaline solution at a middle portion and an aqueous weak alkaline solution at an upper portion, removing a neutralized oil phase containing the carboxylic acid ester from the top of the column and removing an aqueous phase from the bottom, thereby continuously neutralizing the reaction solution.

Process for producing carboxylic acid ester

A stabilized resin composition comprising a resin, a piperidine derivative represented by the formula (III) ##STR1## wherein R.sub.1 is a hydrogen atom or an alkyl group having 1 to 3 carbom atoms; R.sub.2 is a hydrogen atom or an alkyl group having from 1 to 2 carbon atoms; and R.sub.3 and R.sub.4 are each independently an alkyl group having 1 to 12 carbon atoms, a phenol-type antioxidant and a sulfur-containing antioxidant. The composition simultaneously meets heat resistance, oxidation resistance and light resistance requirements.

Process for producing piperidine derivative and stabilized resin

An ultraviolet ray absorbing agent comprising as an active ingredient a spiro compound having a spiro ring structure in the molecule, said spiro compound being represented by the general formula ##STR1## wherein, Y is ##STR2## A is ##STR3## R.sub.1 is hydrogen, halogen, lower alkyl of 1 to 4 carbon atoms, lower alkoxyl of 1 to 4 carbon atoms, carboxyl, or sulfo, R.sub.2 is hydrogen or alkyl of 1 to 12 carbon atoms, R.sub.3 and R.sub.4 are alkyls of 1 to 12 carbon atoms, X is methylene, oxygen, imino, sulfur, sulfinyl, or sulfonyl, and n is an integer of 1 to 12.

Ultraviolet ray absorbing agent

3,9-bis{2-[3-(3-tert-butyl-4-hydroxy-5-methylphenyl) propionyloxy]-1,1-dimethylethyl}-2,4,8,10-tetraoxaspiro[5.5] undecane having a novel crystalline structure which, when subjected to Cu-K.sub..alpha. X-ray diffraction, shows sharp X-ray diffraction peaks at angles of diffraction, 2.theta.=4.2.degree. and 2.theta.=10.6.degree.. Also provided is a method for producing this compound, using a certain recrystallization solvent.

Production of hydroxyphenylpropionic acid ester having a novel

A process for producing a bisphenol compound useful as deterioration preventor capable of stabilizing organic substances against the decompositions caused by heat, light and oxygen, represented by the following general formula: ##STR1## wherein R.sub.1 represents alkyl group having 1 to 3 carbon atoms, alkenyl group having 2 to 4 carbon atoms, phenyl group or 2-phenylethenyl group; R.sub.2 represents alkyl group having 1 to 5 carbon atoms, or cyclohexyl group; R.sub.3 represents alkyl group having 1 to 9 carbon atoms, cyclohexyl group or phenyl group; and R.sub.4 represents alkyl group having 1 to 11 carbon atoms or phenyl group, which comprises reacting a carboxylic acid represented by the following general formula: ##STR2## wherein R.sub.1 is as defined above, with a bisphenol compound represented by the following general formula: ##STR3## wherein R.sub.2, R.sub.3 and R.sub.4 are as defined above, by the use of a halogenating agent in the presence of a dehydrohalogenating agent, as well as butadiene polymer compositions containing said bisphenol compounds.

Thermally stabilized butadiene resins containing a hindered phenolic

3,9-bis{2-[3-(3-tert-butyl-4-hydroxy-5-methylphenyl) propionyloxy]-1,1-dimethylethyl}-2,4,8,10-tetraoxaspiro[5.5] undecane having a novel crystalline structure which, when subjected to Cu-K.sub..alpha. X-ray diffraction, shows sharp X-ray diffraction peaks at angles of diffraction, 2.theta.=4.2.degree. and 2.theta.=10.6.degree.. Also provided is a method for producing this compound.

Hydroxyphenylpropionic acid ester with novel crystalline structure and

Method for producing 3,9-bis{2-[3-(3-tert-butyl-4-hydroxy-5-methylphenyl)propionyloxy]-1,1-dime thylethyl}-2,4,8,10-tetraoxaspiro[5.5]undecane by ester exchange of a 3-(3-tert-butyl-4-hydroxy-5-methylphenyl)-propionic acid ester with 3,9-bis(2-hydroxy-1,1-dimethylethyl)-2,4,8,10-tetraoxaspiro[5.5]-undecane at a temperature of 170.degree.-250.degree. C. using a calcium compound as a catalyst in an amount of 0.05-1.5 moles per mole of the 3,9-bis(2-hydroxy-1,1-dimethylethyl)-2,4,8,10-tetraoxaspiro[5.5]-undecane.

Growing community of inventors

Osaka, Japan

Haruki Okamura